A patient death in a phase 1 trial of Mersana Therapeutics’ antibody-drug ... which is developing the STING agonist in collaboration with GSK under the terms of a $1.3 billion option deal ...
Hosted on MSN2mon
Mersana falls after early-stage trial data for lead cancer therapyCancer drug developer Mersana Therapeutics (NASDAQ:MRSN) hit a 52-week low on Friday after sharing early clinical results from a Phase 1 trial for its lead candidate emiltatug ledadotin (Emi-Le ...
Mersana plans to continue enrolling patients in dose escalation and expects to present initial clinical pharmacodynamic STING activation data for XMT-2056 in 2025. Mersana continues to advance its ...
Mersana plans to continue enrolling patients in dose escalation and expects to present initial clinical pharmacodynamic STING activation data for XMT-2056 in 2025. Mersana continues to advance its ...
Mersana plans to continue enrolling patients in dose escalation and expects to present initial clinical pharmacodynamic STING activation data for XMT-2056 in 2025. Mersana continues to advance its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback